



ECOMPASS Meta-Analysis

Cerebrolysin enhances motor recovery and prevents from neuronal degeneration

Positive effects in Ischemic STROKE patients

Cerebrolysin combined with rehabilitation enhances motor recovery and prevents neural network degeneration in ischemic stroke patients with severe motor deficits. *Journal of Personalized Medicine* 2021;11(6):545.

ECOMPASS Meta-Analysis results

- Enhances motor recovery
- Prevents from degeneration

Cerebrolysin®
Reconnecting Neurons.
Empowering for Life.



Cerebrolysin protects consequences of a stroke!

Enhancement of patient mobility with Cerebrolysin

→ Cerebrolysin provides improvement of motor function

Cerebrolysin prevents degeneration of the neuronal tissue

→ Less degenerative changes in the motor related tracts



full article

Title: Cerebrolysin Combined with Rehabilitation Enhances Motor Recovery and Prevents Neural Network Degeneration in Ischemic Stroke Patients with Severe Motor Deficits

Patients: 59 Cerebrolysin group + 51 Placebo group = 110 stroke patients in total from two phase IV, multicenter, randomized, double-blinded, placebo-controlled trials

Link: <https://pubmed.ncbi.nlm.nih.gov/34208352/>

Copyright © 2022 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria.

ABBREVIATED PRESCRIBING INFORMATION - Cerebrolysin. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of porcine brain-derived peptide preparation (Cerebrolysin concentrate) in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: Organic, metabolic and neurodegenerative disorders of the brain, especially senile dementia of Alzheimer's type - Post-apoplectic complications - Craniocerebral trauma; post-operative trauma, cerebral contusion or concussion. Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics. (Reference SPC - CCDS Version 1.0/Jan 28 2014)

EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria, www.everpharma.com, www.cerebrolysin.com